Trials / Completed
CompletedNCT06708091
Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
A Retrospective Chart Review Combined With a Prospective Cross-sectional Survey and Interviews on Patients With Type 2 Diabetes Mellitus to Assess Effectiveness of Adding SodiumGlucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 537 (actual)
- Sponsor
- Servier Affaires Médicales · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy. The primary objective is to determine the effectiveness of adding SGLT2i to gliclazide MR-based therapy in patients with T2DM, as measured by HbA1c changes.
Conditions
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2024-11-27
- Last updated
- 2024-11-27
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06708091. Inclusion in this directory is not an endorsement.